Safety and Feasibility of a Lower Dose Intravenous TPA Therapy for Ischemic Stroke beyond the First Three Hours

Background: The most common reason that patients do not receive intravenous tissue plasminogen activator (TPA) is the inability to meet the strict 3-hour treatment window. The risk/benefit ratio is more unfavorable beyond this time, but some patients might still benefit. We designed a pilot study with the hypothesis that lower dose TPA might be safe in selected patients treated beyond 3 h. Subjects and Methods: To determine the range of symptomatic hemorrhage and good outcome, we prospectively gave IV TPA 0.6 mg/kg up to 60 mg (15% bolus, 85% infusion over 30 min) to patients with ischemic stroke beyond the first 3 h after last known to be normal. Other eligibility criteria were: NIH Stroke Scale ≧4, normal head CT scan, and clinical suspicion or transcranial Doppler (TCD) evidence of a proximal arterial occlusion. Results: 28 patients were treated, median age 65 (range 24–88) years, median baseline NIHSS score 18 (range 7–34) points. TPA bolus was given 372 ± 158 min after stroke onset (range 189–720). Symptomatic hemorrhage occurred in 3/28 (11%) patients, including 1 fatal bleed. Overall mortality was 6/28 (21%). Partial or complete recanalization was found in 8/20 (40%) TCD monitored patients within 2 h after TPA bolus. Early major improvement occurred in 4/28 (14%) patients. Conclusions: Lower dose IV TPA in patients presenting beyond 3 h carries a risk of intracerebral hemorrhage. However, recanalization with dramatic recovery can still occur.

[1]  A. Demchuk,et al.  Derivation of Transcranial Doppler Criteria for Rescue Intra-arterial Thrombolysis: Multicenter Experience From the Interventional Management of Stroke Study , 2005, Stroke.

[2]  M. Edwards,et al.  Trial , 2004, The Lancet.

[3]  Ims Study Investigators.  Combined Intravenous and Intra-Arterial Recanalization for Acute Ischemic Stroke: The Interventional Management of Stroke Study , 2004, Stroke.

[4]  Scott Hamilton,et al.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.

[5]  A. Alexandrov,et al.  Ischemic Stunning of the Brain: Early Recanalization Without Immediate Clinical Improvement in Acute Ischemic Stroke , 2004, Stroke.

[6]  R. Grubb,et al.  Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association , 2003, Stroke.

[7]  A. Alexandrov,et al.  Is the Benefit of Early Recanalization Sustained at 3 Months?: A Prospective Cohort Study , 2003, Stroke.

[8]  Werner Hacke,et al.  Imaging-Based Decision Making in Thrombolytic Therapy for Ischemic Stroke: Present Status , 2003, Stroke.

[9]  C. Graffagnino,et al.  Nonocclusion and spontaneous recanalization rates in acute ischemic stroke: a review of cerebral angiography studies. , 2002, Archives of neurology.

[10]  I. König,et al.  Predicting functional outcome and survival after acute ischemic stroke , 2002, Journal of Neurology.

[11]  Marc Fisher,et al.  Thrombolytic Therapy Within 3 to 6 Hours After Onset of Ischemic Stroke: Useful or Harmful? , 2002, Stroke.

[12]  Jean-Philippe Thiran,et al.  Prognostic accuracy of cerebral blood flow measurement by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients , 2002, Annals of neurology.

[13]  J. Arenillas,et al.  Time Course of Tissue Plasminogen Activator–Induced Recanalization in Acute Cardioembolic Stroke: A Case-Control Study , 2001, Stroke.

[14]  A. Kassam,et al.  CT-Based Assessment of Acute Stroke: CT, CT Angiography, and Xenon-Enhanced CT Cerebral Blood Flow , 2001, Stroke.

[15]  J. Arenillas,et al.  Timing of Spontaneous Recanalization and Risk of Hemorrhagic Transformation in Acute Cardioembolic Stroke , 2001, Stroke.

[16]  Erich Bluhmki,et al.  Risk Factors for Severe Hemorrhagic Transformation in Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Secondary Analysis of the European-Australasian Acute Stroke Study (ECASS II) , 2001, Stroke.

[17]  A. Alexandrov,et al.  Thrombolysis in Brain Ischemia (TIBI) Transcranial Doppler Flow Grades Predict Clinical Severity, Early Recovery, and Mortality in Patients Treated With Intravenous Tissue Plasminogen Activator , 2001, Stroke.

[18]  J. Broderick,et al.  Predicting prognosis after stroke , 2000, Neurology.

[19]  J. Grotta,et al.  Finding the Most Powerful Measures of the Effectiveness of Tissue Plasminogen Activator in the NINDS tPA Stroke Trial , 2000, Stroke.

[20]  A. Demchuk,et al.  Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy , 2000, The Lancet.

[21]  A. Alexandrov,et al.  Transcranial doppler ultrasound criteria for recanalization after thrombolysis for middle cerebral artery stroke. , 2000, Stroke.

[22]  S Hamilton,et al.  The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. , 2000, Stroke.

[23]  Xin Qun Wang,et al.  A predictive risk model for outcomes of ischemic stroke. , 2000, Stroke.

[24]  G. Albers,et al.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.

[25]  J. Grotta,et al.  Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. , 1999, Stroke.

[26]  R. Higashida,et al.  Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .

[27]  P D Lyden,et al.  Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. , 1999, Stroke.

[28]  A. Alexandrov,et al.  Yield of transcranial Doppler in acute cerebral ischemia. , 1999, Stroke.

[29]  W R Clarke,et al.  Baseline NIH Stroke Scale score strongly predicts outcome after stroke , 1999, Neurology.

[30]  T Brott,et al.  Cincinnati Prehospital Stroke Scale: reproducibility and validity. , 1999, Annals of emergency medicine.

[31]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[32]  B. Tilley,et al.  Myths regarding the NINDS rt-PA Stroke Trial: setting the record straight. , 1997, Annals of emergency medicine.

[33]  G. Hankey,et al.  Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. , 1996, JAMA.

[34]  Fausto Viader,et al.  Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra , 1996, Annals of neurology.

[35]  M. Hommel,et al.  Thrombolytic therapy with streptokinase in acute ischemic stroke. , 1996, The New England journal of medicine.

[36]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[37]  L. Munari,et al.  RANDOMIZED CONTROLLED TRIAL OF STREPTOKINASE, ASPIRIN, AND COMBINATION OF BOTH IN TREATMENT OF ACUTE ISCHEMIC STROKE , 1995 .

[38]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[39]  W. Hacke,et al.  Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke , 1992, Annals of neurology.

[40]  J. Marler,et al.  Urgent Therapy for Stroke: Part II. Pilot Study of Tissue Plasminogen Activator Administered 91-180 Minutes From Onset , 1992, Stroke.

[41]  J. Broderick,et al.  Urgent Therapy for Stroke: Part I. Pilot Study of Tissue Plasminogen Activator Administered Within 90 Minutes , 1992, Stroke.

[42]  A. Thiel,et al.  Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia. , 2001, Brain : a journal of neurology.

[43]  A. Demchuk,et al.  Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. , 2000, Lancet.

[44]  J. Broderick,et al.  Acute stroke: delays to presentation and emergency department evaluation. , 1999, Annals of emergency medicine.

[45]  R. Higashida,et al.  PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. , 1998, Stroke.

[46]  P Trouillas,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. , 1998, Lancet.

[47]  Nirds,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group , 1995 .

[48]  E. O. Bregman,et al.  The Present Status. , 1926 .